SAN
JOSE, Calif., Aug. 31,
2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"
or the "Company") (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer, today announced that
management will participate in two investor conferences in
September.
- H.C. Wainwright 25th Annual Global Investment
Conference: Anixa's pre-recorded presentation will be available
on demand during the event for all registered attendees. Beginning
on Monday, September 11, 2023, the
presentation will also be available on the Company's website at
Investor Relations/Events & Presentations.
- 2023 Cantor Global Healthcare Conference: Anixa
management is scheduled to present on Thursday, September 28, 2023 at 8:00 AM ET in New York
City. The presentation will be broadcast live and archived
on the Company's website at Investor Relations/Events &
Presentations.
Management will be available for one-on-one meetings with
interested investors at both conferences.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the
treatment and prevention of cancer. Anixa's therapeutic
portfolio consists of an ovarian cancer immunotherapy program that
uses a novel type of CAR-T known as chimeric endocrine receptor
T-cell (CER-T) technology, and is being developed in collaboration
with Moffitt Cancer Center. The Company's vaccine portfolio
includes a novel vaccine being developed in collaboration with
Cleveland Clinic to prevent breast cancer – specifically triple
negative breast cancer (TNBC), the most lethal form of the disease
– as well as a vaccine to prevent ovarian cancer. These
vaccine technologies focus on immunizing against "retired" proteins
that have been found to be expressed in certain forms of cancer.
Anixa's unique business model of partnering with
world-renowned research institutions on clinical development allows
the Company to continually examine emerging technologies in
complementary fields for further development and
commercialization. To learn more, visit www.anixa.com or
follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include,
but are not limited to, those factors set forth in "Item 1A - Risk
Factors" and other sections of our most recent Annual Report on
Form 10-K as well as in our Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. We undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except
as required by law. You are cautioned not to unduly rely on
such forward-looking statements when evaluating the information
presented in this press release.
Contacts:
Stephen Kilmer
Investor Relations
skilmer@anixa.com
646-274-3580
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-participate-in-september-investor-conferences-301914455.html
SOURCE Anixa Biosciences, Inc.